Breast Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or  via email
CSmith@GabrailCancerCenter.com.

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

An Open Label Study of SC-005 in Subjects with Triple Negative Breast Cancer (TNBC)

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refactory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H- CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

Return to Clinical Trials at GCC